Literature DB >> 12132043

Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant.

R Martino1, M D Caballero, J de la Serna, J L Díez-Martín, A Urbano-Ispízua, J F Tomás, J Odriozola, A León, C Canals, J San Miguel, J Sierra.   

Abstract

Standard allogeneic stem cell transplantation (SCT) has been associated with a high transplant-related mortality (TRM) in patients who have failed a prior autologous SCT (ASCT). Reduced-intensity conditioning (RIC) regimens may reduce the toxicities and TRM of traditional myeloablative transplants. We report 46 adults who received a RIC peripheral blood SCT from an HLA-identical sibling in two multicenter prospective studies. The median interval between ASCT and allograft was 16 months, and the patients were allografted due to disease progression (n = 43) and/or secondary myelodysplasia (n = 4). Conditioning regimens consisted of fludarabine plus melphalan (n = 41) or busulphan (n = 5). The 100-day incidence of grade II-IV acute graft-versus-host disease (GVHD) was 42% (24% grade III-IV), and 10/30 evaluable patients developed chronic extensive GVHD. Early complete donor chimerism in bone marrow and peripheral blood was observed in 35/42 (83%) patients, and 16 evaluable patients had complete chimerism 1 year post transplant. With a median follow-up of 358 days (450 in 29 survivors), the 1-year incidence of TRM was 24%, and the 1-year overall (OS) and progression-free survival were 63% and 57%, respectively. Patients who had chemorefractory/ progressive disease, a low performance status or received GVHD prophylaxis with cyclosporine A alone (n = 32) had a 1-year TRM of 35% and an OS of 46%, while patients who had none of these characteristics (n = 32) had a 1-year TRM of 35% and an OS of 46% while patients who had none of these characteristics (n = 14) had a TRM of 0% and an OS of 100%. Our results suggest that adult patients who fail a prior ASCT can be salvaged with a RIC allogeneic PBSCT with a low risk of TRM, although patient selection has a profound influence on early outcome.

Entities:  

Mesh:

Year:  2002        PMID: 12132043     DOI: 10.1038/sj.bmt.1703606

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  4 in total

Review 1.  Who is fit for allogeneic transplantation?

Authors:  H Joachim Deeg; Brenda M Sandmaier
Journal:  Blood       Date:  2010-08-11       Impact factor: 22.113

2.  Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants.

Authors:  Melhem Solh; Claudio Brunstein; Shanna Morgan; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-14       Impact factor: 5.742

3.  Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure.

Authors:  César O Freytes; Mei-Jie Zhang; Jeanette Carreras; Linda J Burns; Robert Peter Gale; Luis Isola; Miguel-Angel Perales; Matthew Seftel; Julie M Vose; Alan M Miller; John Gibson; Thomas G Gross; Philip A Rowlings; David J Inwards; Santiago Pavlovsky; Rodrigo Martino; David I Marks; Gregory A Hale; Sonali M Smith; Harry C Schouten; Simon Slavin; Thomas R Klumpp; Hillard M Lazarus; Koen van Besien; Parameswaran N Hari
Journal:  Biol Blood Marrow Transplant       Date:  2011-12-23       Impact factor: 5.742

4.  Successful reduced-intensity stem cell transplantation from an HLA haploidentical 3-loci-mismatched donor on the basis of fetomaternal microchimerism in a patient with advanced acute myeloid leukemia.

Authors:  Nobuhiko Uoshima; Yuri Kamitsuji; Etsuko Maruya; Hiroh Saji
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.